Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial

被引：2

作者：

Harbeck, N. ^{[1
]}

Vazquez, R. Villanueva ^{[2
]}

Tripathy, D. ^{[3
]}

Lu, Y. ^{[4
]}

De Laurentiis, M. ^{[5
]}

Kuemmel, S. ^{[6
]}

Taylor, D. ^{[7
]}

Bardia, A. ^{[8
]}

Hurvitz, S. ^{[9
]}

Chow, L. ^{[10
]}

Im, S. ^{[11
]}

Franke, F. ^{[12
]}

Hughes, G. ^{[13
]}

Miller, M. ^{[13
]}

Kong, O. ^{[13
]}

Chandiwana, D. ^{[13
]}

Colleoni, M. ^{[14
]}

机构：

[1] Univ Munich LMU, Dept OB & GYN, Breast Ctr, Munich, Germany

[2] Hosp St Joan Despi Moises Broggi, Inst Catala Oncol, Barcelona, Spain

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Natl Taiwan Univ Hosp, Taipei, Taiwan

[5] Ist Nazl Tumori Fdn G Pascale, Naples, Italy

[6] Kliniken Essen Mitte, Breast Unit, Essen, Germany

[7] CHU UCL Namur Site St Elisabeth, Namur, Belgium

[8] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[9] UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[10] Org Oncol & Translat Res, Hong Kong, Hong Kong, Peoples R China

[11] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Seoul, South Korea

[12] Hosp Caridade Ijui, CACON, Ijui, Brazil

[13] Novartis Pharmaceut, E Hanover, NJ USA

[14] Ist Europeo Oncol, Div Med Senol, Milan, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2018年 / 92卷

关键词：

D O I：

10.1016/S0959-8049(18)30260-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1LBA

引用

页码：S3 / S3

页数：1

共 50 条

[1] Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis
Bardia, A.
Campos-Gomez, S.
Hurvitz, S. A.
Lu, Y-S.
Im, S-A.
Franke, F.
Chow, L.
Wheatley-Price, P.
Melo Cruz, F.
Alam, J.
Kong, O.
Diaz-Padilla, I.
Miller, M.
Tripathy, D.
ANNALS OF ONCOLOGY, 2018, 29 : 106 - +
[2] Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)
Harbeck, N.
Villanueva, R.
Franke, F.
Babu, G.
Wheatley-Price, P.
Im, Y-H.
Altundag, K.
Lanoue, B.
Alam, J.
Chandiwana, D.
Colleoni, M.
ANNALS OF ONCOLOGY, 2018, 29
[3] Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis
Hurvitz, Sara A.
Wheatley-Price, Paul
Tripathy, Debu
Lu, Yen-Shen
Chow, Louis
Bachelot, Thomas Denis
Hegg, Roberto
Chia, Stephen K. L.
Yardley, Denise A.
Kong, Oliver
Alam, Jahangir
Diaz-Padilla, Ivan
Baeck, Johan
Bardia, Aditya
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] Ribociclib (RIB) plus non-steroidal aromatase inhibitor (NSAI) plus goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study
Im, S-A.
Sohn, J.
Tripathy, D.
Chow, L.
Lee, K. S.
Jung, K. H.
Babu, G.
Im, Y-H.
El Saghir, N.
Liu, M-C.
Diaz-Padilla, I.
Alam, J.
Kong, O.
Miller, M.
Lu, Y-S.
ANNALS OF ONCOLOGY, 2018, 29
[5] Ribociclib (RIB) plus fulvestrant (FUL) in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses
Neven, P.
Petrakova, K.
Bianchi, G. V.
Merino, L. De la Cruz
Jerusalem, G.
Beck, J. T.
Sonke, G. S.
Chia, S.
Brucker, S.
Wang, Y.
He, W.
Lorenc, K. Rodriguez
Su, F.
Im, S-A.
ANNALS OF ONCOLOGY, 2018, 29 : 113 - +
[6] Ribociclib with a non-steroidal aromatase inhibitor and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 age subgroup analysis
Tripathy, D.
Campos-Gomez, S.
Lu, Y-S
Franke, F.
Bardia, A.
Wheatley-Price, P.
Cruz, F. M.
Hegg, R.
Cardoso, F.
Gaur, A.
Kong, O.
Diaz-Padilla, I.
Miller, M.
Hurvitz, S.
CANCER RESEARCH, 2019, 79 (04)
[7] First-line ribociclib plus letrozole in postmenopausal Asian women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2
Yap, Y. S.
Tseng, L-M.
Blackwell, K. L.
Cameron, D.
Foo, S.
Sriuranpong, V.
Huang, C-S.
Chao, T-Y.
Kim, T-Y.
Chen, S-C.
Jung, K. H.
Lee, K. S.
Sohn, J-H.
Kim, J. H.
Hou, M-F.
Han, Y.
Souami, F.
Dhuria, S.
Miller, M.
Verma, S.
ANNALS OF ONCOLOGY, 2016, 27
[8] Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib plus letrozole: Results from MONALEESA-2.
Verma, Sunil
O'Shaughnessy, Joyce
Burris, Howard A.
Campone, Mario
Alba, Emilio
Chandiwana, David
Manson, Stephanie
Sutradhar, Santosh C.
Monaco, Mauricio
Janni, Wolfgang
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9] Ribociclib plus letrozole in premenopausal patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
Razeq, Hikmat Abdel
Cottu, Paul
Ring, Alistair
De laurentiis, Michelino
Lu, Janice
Azim, Hamdy
Zamagni, Claudio
Zhou, Katie
Wu, Jiwen
Menon-Singh, Lakshmi
Martin, Miguel
CANCER RESEARCH, 2021, 81 (04)
[10] COST-EFFECTIVENESS OF RIBOCILIB PLUS NONSTEROIDAL AROMATASE INHIBITOR (NSAI) IN HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE
Stellato, D.
Thabane, M.
Chandiwana, D.
Lanoue, B.
Delea, T. E.
VALUE IN HEALTH, 2020, 23 : S39 - S39

← 1 2 3 4 5 →